MCID: MLG164
MIFTS: 26

Malignant Epithelial Tumor of Ovary

Categories: Cancer diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Malignant Epithelial Tumor of Ovary

MalaCards integrated aliases for Malignant Epithelial Tumor of Ovary:

Name: Malignant Epithelial Tumor of Ovary 58
Ovarian Malignant Epithelial Tumor 58
Epithelial Cancer of Ovary 58
Ovarian Epithelial Cancer 58

Classifications:

Orphanet: 58  
Rare gynaecological and obstetric diseases


External Ids:

UMLS via Orphanet 72 C0677886
Orphanet 58 ORPHA398934

Summaries for Malignant Epithelial Tumor of Ovary

MalaCards based summary : Malignant Epithelial Tumor of Ovary, also known as ovarian malignant epithelial tumor, is related to ovarian epithelial cancer and malignant non-epithelial tumor of ovary. The drugs Docetaxel and Topotecan have been mentioned in the context of this disorder. Affiliated tissues include ovary, t cells and bone.

Related Diseases for Malignant Epithelial Tumor of Ovary

Diseases related to Malignant Epithelial Tumor of Ovary via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 21)
# Related Disease Score Top Affiliating Genes
1 ovarian epithelial cancer 12.6
2 malignant non-epithelial tumor of ovary 11.5
3 ovary transitional cell carcinoma 11.3
4 ovarian cancer 10.5
5 serous cystadenocarcinoma 10.1
6 cystadenoma 10.0
7 ovarian cyst 10.0
8 ovarian serous cystadenocarcinoma 10.0
9 prostate cancer 9.8
10 polycystic kidney disease 4 with or without polycystic liver disease 9.8
11 ovarian cancer 1 9.8
12 endometrial cancer 9.8
13 neutropenia 9.8
14 papillary serous adenocarcinoma 9.8
15 transitional cell carcinoma 9.8
16 endometriosis 9.8
17 adenocarcinoma 9.8
18 cystadenocarcinoma 9.8
19 ovary adenocarcinoma 9.8
20 peritonitis 9.8
21 appendicitis 9.8

Graphical network of the top 20 diseases related to Malignant Epithelial Tumor of Ovary:



Diseases related to Malignant Epithelial Tumor of Ovary

Symptoms & Phenotypes for Malignant Epithelial Tumor of Ovary

Drugs & Therapeutics for Malignant Epithelial Tumor of Ovary

Drugs for Malignant Epithelial Tumor of Ovary (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 292)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
2
Topotecan Approved, Investigational Phase 3 123948-87-8, 119413-54-6 60700
3
Gemcitabine Approved Phase 3 95058-81-4 60750
4
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
5
Melphalan Approved Phase 3 148-82-3 460612 4053
6
Sodium citrate Approved, Investigational Phase 3 68-04-2
7
Tamoxifen Approved Phase 3 10540-29-1 2733526
8
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
9
Ondansetron Approved Phase 3 99614-02-5 4595
10
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
11
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
12
Epirubicin Approved Phase 3 56420-45-2 41867
13
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
14
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
15
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
16
Captopril Approved Phase 3 62571-86-2 44093
17
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
18
Ribavirin Approved Phase 3 36791-04-5 37542
19
Palivizumab Approved, Investigational Phase 3 188039-54-5
20
Acyclovir Approved Phase 3 59277-89-3 2022
21
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 2826718 468682
22
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
23
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
24
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
25
Bevacizumab Approved, Investigational Phase 3 216974-75-3
26
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 38904 498142
27
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
28
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
29
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
30
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
31
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
32
Polyestradiol phosphate Approved Phase 3 28014-46-2
33
Mycophenolic acid Approved Phase 3 24280-93-1 446541
34
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
35
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 3 53-43-0 9860744
36
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 3 65-23-6 1054
37 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
38 Anti-Infective Agents Phase 3
39 Anti-Bacterial Agents Phase 3
40 Liver Extracts Phase 3
41 topoisomerase I inhibitors Phase 3
42 Antiviral Agents Phase 3
43 Antimetabolites Phase 3
44 Cola Phase 3
45 Gastrointestinal Agents Phase 3
46
Liposomal doxorubicin Phase 3 31703
47 Citrate Phase 3
48 Estrogen Antagonists Phase 3
49 Estrogen Receptor Antagonists Phase 3
50 Anesthetics Phase 3

Interventional clinical trials:

(show top 50) (show all 424)
# Name Status NCT ID Phase Drugs
1 Phase III Randomized Study of Adjuvant Therapy With a Platinum-Containing Regimen (e.g., CBDCA or CAP: CTX/DOX/CDDP) vs No Adjuvant Therapy in Patients With Fully Resected Early Stage Ovarian Cancer Unknown status NCT00002477 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride
2 Randomized Double-Blind Controlled Phase III Trial of Hyperbaric Oxygen Therapy in Patients Suffering Long-Term Adverse Effects of Radiotherapy for Pelvic Cancer (HOT II) Unknown status NCT01087268 Phase 3
3 Multicenter Randomized Survival Study of Monoclonal Antibody Radioimmunotherapy: A Multinational Study in Patients With Ovarian Carcinoma Using the HMFG1 Antibody Labeled With 90Yttrium Unknown status NCT00004115 Phase 3
4 A Randomized Phase II/III Trial Comparing Carboplatin-Ifosfamide (IC)-Chemotherapy Vs. IC-Chemotherapy Combined With Extreme Whole Body Hyperthermia In Patients With Recurrence Of Epithelial Ovarian Carcinoma: DOLPHIN-1-STUDY Unknown status NCT00045461 Phase 2, Phase 3 carboplatin;ifosfamide
5 Multi-Center, Randomized, Double-Blind, Phase III Efficacy Study Comparing Phenoxodiol in Combination With Carboplatin Versus Carboplatin With Placebo in Patients With Platinum-Resistant or Platinum-Refractory Late-Stage Epithelial Ovarian, Fallopian or Primary Peritoneal Cancer Following at Least Second Line Platinum Therapy Completed NCT00382811 Phase 3 phenoxodiol;carboplatin;placebo
6 Amifostine as a Toxicity Protectant in Ovarian Cancer in Chemotherapy Treated Patients: A Pilot Phase III Randomized Controlled Trial Completed NCT00004166 Phase 3 amifostine trihydrate
7 ICON7 - A Randomised, Two-Arm, Multi-Centre Gynaecologic Cancer InterGroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin and Paclitaxel) in Patients With Epithelial Ovarian Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
8 Phase III Multicenter Study in Epithelial Ovarian Carcinoma FIGO Stage IIB-IV Comparing Treatment With Paclitaxel and Carboplatin to Paclitaxel and Carboplatin Sequentially Followed by Topotecan Completed NCT00006454 Phase 3 carboplatin;paclitaxel;topotecan hydrochloride
9 A Randomized Phase III Trial of Sequential High Dose Chemotherapy or Standard Chemotherapy for Optimally Debulked FIGO Stage III and IV Ovarian Cancer Completed NCT00004921 Phase 3 carboplatin;cyclophosphamide;melphalan;paclitaxel
10 A Randomized, Prospective Phase III Comparison of Paclitaxel-Carboplatin Versus Docetaxel-Carboplatin as First Line Chemotherapy in Stage Ic-IV Epithelial Ovarian Cancer Completed NCT00003998 Phase 3 carboplatin;docetaxel;paclitaxel
11 Phase III Randomized Study of TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Liposomal Doxorubicin (Doxil) as Second-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer [ASSIST-3] Completed NCT00102973 Phase 3 TLK286 in Combination with Carboplatin;Doxorubicin HCl Liposome Injection
12 SCOTROC 4: A Prospective, Multicentre, Randomised Trial Of Carboplatin Flat Dosing Vs Intrapatient Dose Escalation In First Line Chemotherapy Of Ovarian, Fallopian Tube And Primary Peritoneal Cancers Completed NCT00098878 Phase 3 carboplatin
13 A Randomized Feasibility Trial to Determine the Impact of Timing of Surgery and Chemotherapy in Newly Diagnosed Patients With Advanced Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Carcinoma Completed NCT00075712 Phase 2, Phase 3 carboplatin;paclitaxel
14 A Multi-National Randomized Phase-III GCIG Intergroup-Study Comparing 1st-line Chemotherapy With Gemcitabine/Paclitaxel/Carboplatin vs Paclitaxel/Carboplatin In Previously Untreated Patients With Epithelial Ovarian Cancer FIGO Stages I-IV Completed NCT00052468 Phase 3 TCG;TC
15 A Randomized, Multicenter, Phase III Study of Erlotinib Versus Observation in Patients With no Evidence of Disease Progression After First Line, Platinum-Based Chemotherapy For High-Risk Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00263822 Phase 3 erlotinib hydrochloride
16 A Randomized Phase III Double-Blind Study Of Ondansetron And Dexamethasone Versus Ondansetron And Placebo In The Prophylaxis Of Radiation-Induced Emesis Completed NCT00016380 Phase 3 dexamethasone;ondansetron
17 A Randomized Phase III Study Comparing Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Epithelial Ovarian Carcinoma Who Failed First-Line Platinum-Based Therapy Completed NCT00006453 Phase 3 carboplatin;gemcitabine hydrochloride
18 A Randomized Phase III Trial of IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days x 3 Courses Plus Low Dose Paclitaxel 40 mg/m2/wk Versus IV Carboplatin (AUC 6) and Paclitaxel 175 mg/m2 Q 21 Days x 3 Courses Plus Observation in Patients With Early Stage Ovarian Carcinoma Completed NCT00003644 Phase 3 carboplatin;paclitaxel
19 Phase III Randomized Trial of 12 Months vs. 3 Months of Paclitaxel in Patients With Advanced Ovarian Cancer Who Attain a Clinically Defined Complete Response (CR) Following Platinum/Paclitaxel-Based Chemotherapy Completed NCT00003120 Phase 3 paclitaxel
20 A Phase III Randomized Trial of Cisplatin (NSC #119875) With Paclitaxel (NSC #125973) Administered by Either 24 Hour Infusion or 96 Hour Infusion in Patients With Selected Stage III and Stage IV Epithelial Ovarian Cancer and Primary Peritoneal Carcinoma Completed NCT00002717 Phase 3 cisplatin;paclitaxel
21 A Phase III Study of Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients With Recurrent Epithelial Ovarian and Peritoneal Carcinoma After Failure of Initial Platinum-Based Chemotherapy Completed NCT00043082 Phase 3 carboplatin;pegylated liposomal doxorubicin hydrochloride
22 A Phase III Study of Cisplatin Plus Topotecan Followed by Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Carboplatin as First Line Chemotherapy in Women With Newly Diagnosed Advanced Epithelial Ovarian Cancer Completed NCT00028743 Phase 3 carboplatin;cisplatin;paclitaxel;topotecan hydrochloride
23 A Randomised Trial of Interval Debulking Surgery in Epithelial Ovarian Cancer Suboptimally Debulked at Primary Surgery Completed NCT00003695 Phase 3 chemotherapy
24 Randomized Trial on Chemosensitivity Testing in Advanced Primary Ovarian Carcinoma (Phase III) Completed NCT00003214 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride;in vitro sensitivity-directed chemotherapy;paclitaxel
25 A RANDOMISED TRIAL OF PACLITAXEL (TAXOL) IN COMBINATION WITH PLATINUM CHEMOTHERAPY VS. CONVENTIONAL PLATINUM-BASED CHEMOTHERAPY IN THE TREATMENT OF WOMEN WITH RELAPSED OVARIAN CANCER Completed NCT00002894 Phase 3 carboplatin;cisplatin;paclitaxel
26 A PHASE III RANDOMIZED STUDY OF CISPLATIN (NSC #119875) AND TAXOL (PACLITAXEL) (NSC #125973) WITH INTERVAL SECONDARY CYTOREDUCTION VERSUS CISPLATIN AND PACLITAXEL IN PATIENTS WITH SUBOPTIMAL STAGE III & IV EPITHELIAL OVARIAN CARCINOMA Completed NCT00002568 Phase 3 cisplatin;paclitaxel
27 A Randomized Trial of Paclitaxel/Epirubicin/Carboplatin Combination (TEC) Versus Paclitaxel/Carboplatin (TC) in the Treatment of Women With Advanced Ovarian Cancer Completed NCT00004934 Phase 3 carboplatin;epirubicin hydrochloride;paclitaxel
28 A Randomized Study Of Tamoxifen Versus Thalidomide (NSC# 66847) In Patients With Biochemical-Recurrence-Only Epithelial Ovarian Cancer, Cancer Of The Fallopian Tube, And Primary Peritoneal Carcinoma After First Line Chemotherapy Completed NCT00041080 Phase 3 tamoxifen citrate;thalidomide
29 A Randomized Phase III Study Comparing Upfront Debulking Surgery Versus Neo-Adjuvant Chemotherapy in Patients With Stage IIIC or IV Epithelial Ovarian Carcinoma Completed NCT00003636 Phase 3 carboplatin;cisplatin
30 Phase III Study of Captopril in Patients Undergoing Autologous Bone Marrow/Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
31 A Randomized, Comparative Study of Itraconazole Versus Fluconazole for Prevention of Aspergillus Infections in Peripheral Blood Stem Cell and Marrow Transplant Recipients Completed NCT00003883 Phase 3 fluconazole;itraconazole
32 A Randomized Double-Blind Placebo-Controlled Phase III Study To Evaluate The Safety And Efficacy Of Palivizumab Combined With Aerosolized Ribavirin Compared To Ribavirin Alone To Treat RSV Pneumonia In Patients With Bone Marrow Transplants (BMT) Completed NCT00014391 Phase 3 ribavirin
33 A Phase III Multicenter Study of Cytomegalovirus Prophylaxis With Valacyclovir for the Prevention of Serious Fungal and Bacterial Infections Among Cytomegalovirus Seronegative Recipients of Cytomegalovirus Seropositive Sx Stem Cell Transplants Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
34 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
35 A Phase III Randomized Trial of Intravenous Paclitaxel and Cisplatin Versus Intravenous Paclitaxel, Intraperitoneal Cisplatin and Intraperitoneal Paclitaxel in Patients With Optimal Stage III Epithelial Ovarian Carcinoma or Primary Peritoneal Carcinoma Completed NCT00003322 Phase 3 cisplatin;paclitaxel
36 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
37 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
38 A Randomised Trial in Relapsed Ovarian Cancer: Early Treatment Based on CA 125 Levels Alone Vs. Delayed Treatment Based On Conventional Clinical Indicators Completed NCT00002895 Phase 3 chemotherapy
39 Vaginal DHEA for Vaginal Symptoms: A Phase III Randomized, Double Blind, Placebo- Controlled Trial Completed NCT01376349 Phase 3 prasterone
40 A Phase III Randomized Trial Of Paclitaxel And Carboplatin Versus Triplet Or Sequential Doublet Combinations In Patients With Epithelial Ovarian Or Primary Peritoneal Carcinoma Completed NCT00011986 Phase 3 Paclitaxel;Carboplatin;Gemcitabine Hydrochloride;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
41 A Double-Blind Randomized Trial of Pyridoxine Versus Placebo for the Prevention of Doxil-Related Palmar-Plantar Erythrodysesthesia (Hand-Foot Syndrome) Completed NCT00245050 Phase 3 Placebo;doxorubicin HCL liposome
42 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
43 Evaluation of Secondary Cytoreductive Surgery in Platinum-Sensitive Recurrent Ovarian Cancer: A Phase III, Multicenter, Randomized Trial Recruiting NCT01611766 Phase 3 Salvage Chemotherapy
44 A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
45 GOG-0262: A Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination With Carboplatin With or Without Concurrent and Consolidation Bevacizumab (NSC #704865) in the Treatment of Primary Stage II, III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer and ACRIN 6695: Perfusion CT Imaging to Evaluate Treatment Response in Patients Participating in GOG-0262 Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
46 Assessment of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in First or Secondary Platinum-resistant Recurrent Ovarian Epithelial Cancer Not yet recruiting NCT03220932 Phase 3 Chemotherapy and bevacizumab (CT-BEV)
47 A Phase III Randomized Study Evaluating Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) in the Treatment of Relapse Ovarian Cancer Suspended NCT01376752 Phase 3 HIPEC
48 A Randomized Double-Blind Phase 3 Trial Comparing EC145 and Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®) in Combination Versus PLD in Participants With Platinum-Resistant Ovarian Cancer Suspended NCT01170650 Phase 3 EC145;Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®);placebo;EC20
49 A RANDOMIZED, CONTROLLED TRIAL OF SALVAGE THERAPY WITH PACLITAXEL AND CARBOPLATIN VERSU SALVAGE THERAPY WITH STEM CELL SUPPORTED HIGH-DOSE CARBOPLATIN, MITOXANTRONE AND CYCLOPHOSPHAMIDE IN PATIENTS WITH PERSISTENT LOW VOLUME OVARIAN CANCER AND RESPONSE TO PRIMARY THERAPY Terminated NCT00002819 Phase 3 carboplatin;cyclophosphamide;mitoxantrone hydrochloride;paclitaxel
50 Phase 3 Randomized Study of TLK286 (Telcyta®) in Combination With Liposomal Doxorubicin (Doxil/Caelyx)Versus Liposomal Doxorubicin (Doxil/Caelyx) as Second-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer (ASSIST-5) Terminated NCT00350948 Phase 3 Telcyta;Liposomal Doxorubicin

Search NIH Clinical Center for Malignant Epithelial Tumor of Ovary

Genetic Tests for Malignant Epithelial Tumor of Ovary

Anatomical Context for Malignant Epithelial Tumor of Ovary

MalaCards organs/tissues related to Malignant Epithelial Tumor of Ovary:

40
Ovary, T Cells, Bone, Bone Marrow, Breast, Lung, Testes

Publications for Malignant Epithelial Tumor of Ovary

Articles related to Malignant Epithelial Tumor of Ovary:

(show top 50) (show all 307)
# Title Authors PMID Year
1
Association of PD-L1 expression by immunohistochemistry and gene microarray with molecular subtypes of ovarian tumors. 61
32404957 2020
2
Does Saving Uterus Save Ovaries? 61
32255946 2020
3
Differentiation of borderline tumors from type I ovarian epithelial cancers on CT and MR imaging. 61
32162020 2020
4
HSPA1A, HSPA1L and TRAP1 heat shock genes may be associated with prognosis in ovarian epithelial cancer. 61
31897148 2020
5
Overexpression of DUSP6 enhances chemotherapy-resistance of ovarian epithelial cancer by regulating the ERK signaling pathway. 61
32231719 2020
6
Ovarian Cancer Incidence in the Multi-Ethnic Asian City-State of Singapore 1968-2012. 61
31870095 2019
7
Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy. 61
31602489 2019
8
Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. 61
31684686 2019
9
Differential Expression Pattern of Epithelial Mesenchymal Transition Gens: AXL, GAS6, Claudin-1, and Cofilin-1, in Different Stages of Epithelial Ovarian Cancer. 61
31700829 2019
10
Genistein upregulates cyclin D1 and CDK4 expression and promotes the proliferation of ovarian cancer OVCAR-5 cells. 61
31465770 2019
11
Expression levels of MRP1, GST-π, and GSK3β in ovarian cancer and the relationship with drug resistance and prognosis of patients. 61
31289467 2019
12
Prognostic Significance of CD109 Expression in Patients with Ovarian Epithelial Cancer. 61
31316041 2019
13
Magnetic resonance imaging radiomics in categorizing ovarian masses and predicting clinical outcome: a preliminary study. 61
30963272 2019
14
Magnetic resonance imaging in categorization of ovarian epithelial cancer and survival analysis with focus on apparent diffusion coefficient value: correlation with Ki-67 expression and serum cancer antigen-125 level. 61
31242916 2019
15
PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma. 61
31208449 2019
16
Liquid Biopsies for Ovarian Carcinoma: How Blood Tests May Improve the Clinical Management of a Deadly Disease. 61
31167492 2019
17
Mining Featured Biomarkers Linked with Epithelial Ovarian CancerBased on Bioinformatics. 61
30970615 2019
18
[Surgery in early-stage ovarian cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa]. 61
30686727 2019
19
The effects of ovarian cancer cell-derived exosomes on vascular endothelial growth factor expression in endothelial cells. 61
31645849 2019
20
Overexpression of the recently identified oncogene REDD1 correlates with tumor progression and is an independent unfavorable prognostic factor for ovarian carcinoma. 61
30428884 2018
21
Bevacizumab with dose-dense paclitaxel/carboplatin as first-line chemotherapy for advanced ovarian cancer. 61
30059681 2018
22
Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer. 61
29454514 2018
23
Activation of hedgehog signaling and its association with cisplatin resistance in ovarian epithelial tumors. 61
29552194 2018
24
Identification of Genes and Pathways Involved in Ovarian Epithelial Cancer by Bioinformatics Analysis. 61
30210623 2018
25
Splenectomy during cytoreductive surgery in epithelial ovarian cancer. 61
30254490 2018
26
Stably Fluorescent Cell Line of Human Ovarian Epithelial Cancer Cells SK-OV-3ip-red. 61
29124539 2017
27
Generation of induced pluripotent stem cell (iPSC) line from a patient with triple negative breast cancer with hereditary exon 17 deletion of BRCA1 gene. 61
29034880 2017
28
The diagnostic value of determination of serum GOLPH3 associated with CA125, CA19.9 in patients with ovarian cancer. 61
29028099 2017
29
(E)-2-methoxy-4-(3-(4-methoxyphenyl)prop-1-en-1-yl)phenol suppresses ovarian cancer cell growth via inhibition of ERK and STAT3. 61
28277616 2017
30
Detection of OPCML methylation, a possible epigenetic marker, from free serum circulating DNA to improve the diagnosis of early-stage ovarian epithelial cancer. 61
28693156 2017
31
Expression of inflammatory cytokines in ovarian epithelial cancer and their correlation. 61
28685546 2017
32
BRCA1 expression, proliferative and apoptotic activities in ovarian epithelial inclusions. 61
28270171 2017
33
[HORMONE REPLACEMENT THERAPY AFTER GYNECOLOGICAL MALIGNANCIES]. 61
28551932 2017
34
[MicroRNA Analysis in Epithelial Ovarian Cancer]. 61
28471201 2017
35
Epithelial Ovarian Cancer Diagnosis of Second-Harmonic Generation Images: A Semiautomatic Collagen Fibers Quantification Protocol. 61
28469386 2017
36
The prognostic value of KRAS mutation by cell-free DNA in cancer patients: A systematic review and meta-analysis. 61
28796802 2017
37
Role and timing of second-line therapies for patients with recurrent platinum-resistant ovarian epithelial cancer. 61
29953793 2017
38
The American Society of Peritoneal Surface Malignancies Multi-Institution evaluation of 1,051 advanced ovarian cancer patients undergoing cytoreductive surgery and HIPEC: An introduction of the peritoneal surface disease severity score. 61
27792292 2016
39
Novel paradigm for immunotherapy of ovarian cancer by engaging prophylactic immunity against hepatitis B virus. 61
27905089 2016
40
Platelets are not hyperreactive in patients with ovarian cancer. 61
27185008 2016
41
Regulation of exosomes released from normal ovarian epithelial cells and ovarian cancer cells. 61
27714673 2016
42
Epithelialization of mouse ovarian tumor cells originating in the fallopian tube stroma. 61
27602775 2016
43
New halogenated constituents from Mangifera zeylanica Hook.f. and their potential anti-cancer effects in breast and ovarian cancer cells. 61
27224244 2016
44
Candidate genes and pathways downstream of PAX8 involved in ovarian high-grade serous carcinoma. 61
27259239 2016
45
Laparoscopic fertility-sparing surgery for early ovarian epithelial cancer: A multi-institutional experience. 61
27017986 2016
46
Overexpression of Notch3 and pS6 Is Associated with Poor Prognosis in Human Ovarian Epithelial Cancer. 61
27445438 2016
47
Tumor suppressor in lung cancer 1 gene expression in epithelial ovarian cancer. 61
27146728 2016
48
Nedd4L expression is decreased in ovarian epithelial cancer tissues compared to ovarian non-cancer tissue. 61
26554540 2015
49
Ursolic acid inhibits the proliferation of human ovarian cancer stem-like cells through epithelial-mesenchymal transition. 61
26323892 2015
50
Anti-proliferative activity and cell cycle arrest induced by evodiamine on paclitaxel-sensitive and -resistant human ovarian cancer cells. 61
26553648 2015

Variations for Malignant Epithelial Tumor of Ovary

Expression for Malignant Epithelial Tumor of Ovary

Search GEO for disease gene expression data for Malignant Epithelial Tumor of Ovary.

Pathways for Malignant Epithelial Tumor of Ovary

GO Terms for Malignant Epithelial Tumor of Ovary

Sources for Malignant Epithelial Tumor of Ovary

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....